Iodide

Iodide

SCHEMBL16585403

I.c1cnc2nn[nH]c2c1

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.42
METAP1 P53582 2/20 0.38
METAP2 P50579 1/20 0.38
LMNA P02545 1/20 0.35
PARP1 P09874 1/20 0.35
PDE5A O76074 2/20 0.35
AURKA O14965 5/20 0.34
KCNMA1 Q12791 1/20 0.33
TP53 P04637 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
PSMD14 O00487 1/20 0.33
GRM4 Q14833 1/20 0.33
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL40861 0.98
SCHEMBL29376620 0.98
Hydrochloric Acid SCHEMBL29236109 0.96 NUDT1 (0.42) NUDT1METAP1METAP2PARP1PDE5A
SCHEMBL27759739 0.96 NUDT1 (0.42) NUDT1METAP1METAP2PARP1PDE5A
SCHEMBL8038689 0.96 NUDT1 (0.42) NUDT1METAP1METAP2PARP1PDE5A
SCHEMBL21990259 0.96 NUDT1 (0.42) NUDT1METAP1METAP2PARP1PDE5A
SCHEMBL28611928 0.96 NUDT1 (0.42) NUDT1METAP1METAP2PARP1PDE5A
Pyrazine SCHEMBL27939229 0.92 NUDT1 (0.40) NUDT1METAP1METAP2PARP1PDE5A
SCHEMBL29948103 0.92 NUDT1 (0.40) NUDT1METAP1METAP2PARP1PDE5A
SCHEMBL937094 0.90 NUDT1 (0.39) NUDT1METAP1METAP2PARP1PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9738642-B2 Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders BRISTOL-MYERS SQUIBB COMPANY (US) 2017-08-22 US disclosed
US-20160237081-A1 TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS BRISTOL MYERS SQUIBB CO (US) 2016-08-18 US disclosed
EP-3046922-A1 TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS Bristol-Myers Squibb Company (US) 2016-07-27 EP disclosed
WO-2015042243-A1 TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237081-A1 TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS GRM2, GRIK2, GRIA2 NUDT1 3284/4885METAP1 2749/4885METAP2 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.